← Back to TEVAPortrait, one to two pages. Turn on “background graphics” in the print dialog to keep the table rules.
SPZCOTEVA PHARMACEUTICAL INDUSTRIES LTD · TEVAData at close 2026-07-30
Health Care · Pharmaceutical Preparations · NYSE · CIK 818686 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
TEVA close: $8.4 on 2023-07-31 to $35.4 on 2026-07-30.
Daily closing price, split-adjusted to the current basis; 3y shown of 5,295 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
At a glance
Fair value (model)$9.86
Implied upside−72.2%
Valuation confidenceLOW
Price impliesNEVER-OBSERVED · 38.2% growth
Short interest2.8% of sh out
Days to cover6.5d
13F net flow (QoQ)+2.50%
Top-10 13F concentration57.8%
Next report (est.)2026-10-28
Fair value, confidence and the reverse-DCF grade are the MATERIALIZED daily snapshot (the same columns the screener serves), not a live model run. Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
Key fundamentalsFY 2025
P/E (FY)29.3×
Sales (TTM)$14.10B
Trailing returns
YTD+13.5%
1Y+110.4%
3Y+321.5%
5Y+266.9%
10Y−30.6%
Since incept. (ann.)+1.9%
Total return through 2026-07-30 · series begins 2005-07-08. Only the windows this history actually covers are shown.
Risk
Ann. volatility (1Y)41.3%
Ann. volatility (3Y)42.0%
Sharpe (1Y)2.07
Sharpe (3Y)1.36
Max drawdown (1Y)−21.8%
Max drawdown (3Y)−43.7%
Beta (3Y vs SPY)0.64
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
Latest reported quarterslast report 2026-07-29
Period end
Reported
EPS
EPS YoY
Revenue
Rev YoY
2026-06-30
2026-07-29
−$0.49
−304.2%
$4.14B
−0.8%
2026-03-31
2026-04-29
$0.31
+72.2%
$3.98B
+2.3%
2025-12-31
2026-01-28
—
—
$1.50B
−64.5%
2025-09-30
2025-11-05
$0.37
—
$4.48B
+3.4%
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-10-28 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Segment mixFY2025 (ended Dec 2025)
United States 53% · Europe 29% · International Markets 13% · Other Activities 5%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
Basis & disclosures
End-of-day only. Every price on this sheet is a stored CLOSE — the last one is 2026-07-30. Nothing here is live, intraday or delayed-real-time, and the sheet does not update after it is printed.
Nothing is imputed. A figure that is not in the underlying filing or feed renders as “—”. We never fill a gap with an estimate, a peer median or a carried-forward value.
Mixed as-of dates by design. Prices are at the last close; fundamentals are at the latest reported fiscal period; 13F ownership is at the latest filed quarter (45+ days in arrears); short interest is the latest FINRA settlement. Each block states its own basis above.
Not investment advice. Model fair values, reverse-DCF grades and confidence labels are the output of published, disclosed methods on public filings — they are analysis, not a recommendation, a price target or a solicitation.
Fundamentals and ownership derive from SEC EDGAR (and equivalent foreign registers); prices from a licensed end-of-day vendor, shown under a neutral source label. Full methodology at spzco.com/methodology.
Earnings (TTM)$707.0M
ROE21.2%
Net margin8.2%
ROIC43.0%
Debt / equity0.23×
Total debt / EBITDA0.58×
Sales growth 3Y5.0%
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
